Pay in 4 interest-free payments of $6.52 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Andrea Corona Altimmunes GLP-1 drug shows positive results for alcohol use disorder On Tuesday, Altimmune announced topline data from their Phase 2 RECLAIM trial showing that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly reduced the number of heavy drinking days compared to placebo in patients with moderate to severe alcohol use disorder
Semaglutide has also been shown to improve cognitive function in animal models of Alzheimers disease
However, semaglutide may also support blood sugar and appetite regulation for many patients
That does not mean the medication is not working for you
Ideal candidates for this treatment are individuals close to their ideal weight but struggling with localised fat deposits that dont respond to traditional weight loss methods
the Hardesty Family Foundation (W.K.S.)
US$ 26.23
US$ 20.45
US$ 24.79
